Monitor the final pricing and size of the offering when announced, as this will determine the actual dilution impact. Watch for any updates on the company's clinical trial progress and cash runway extension, which will be key indicators of how effectively the raised capital is being deployed.
Price Chart
Executive Summary
Spruce Biosciences is conducting a public offering of common stock and pre-funded warrants to raise capital, with net proceeds intended for advancing pre-commercial activities, clinical trials, and general corporate purposes. The offering includes an over-allotment option and is subject to a 90-day lock-up agreement for insiders. The pre-funded warrants have a nominal $0.01 exercise price and will not generate meaningful proceeds upon exercise.
Key Facts
- Offering includes common stock and pre-funded warrants with a $0.01 exercise price
- Net proceeds will fund pre-commercial activities, clinical trials, and general corporate purposes
- 90-day lock-up agreement for officers, directors, and certain stockholders
- No established market for pre-funded warrants; liquidity will be limited
- Company will receive only nominal proceeds from warrant exercises
Financial Impact
The offering will provide capital for operations, but specific dollar amounts are not disclosed in the filing. The company previously registered a $300 million shelf offering.
Risk Factors
- Significant dilution to existing shareholders from new share issuance
- Limited liquidity for pre-funded warrant holders due to no established trading market
- Company has a history of operating losses and will require additional future funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-163919 |
| Document: 0001193125-26-163919-index-headers.html | 0001193125-26-163919 |
| Document: 0001193125-26-163919-index.html | 0001193125-26-163919 |
| Document: 0001193125-26-163919.txt | 0001193125-26-163919 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 10w ago | 8-K | $47.07 $54.35 | ▲ +15.47% | ▲ +17.36% | $43.99 (−6.54%) |
May 13, 2026 23w ago | 8-K | $57.55 $49.11 | ▼ −14.67% | ▼ −14.06% | $43.99 (−23.56%) |
Apr 21, 2026 26w ago | 424B5 | $52.36 $48.25 | ▼ −7.85% | ▼ −11.01% | $43.99 (−15.99%) |
Apr 20, 2026 27w ago | 424B5 | $51.69 $51.41 | ▼ −0.54% | ▼ −5.46% | $43.99 (−14.90%) |
Mar 9, 2026 33w ago | 8-K | $62.11 $62.15 | ▲ +0.06% | ▲ +2.87% | $43.99 (−29.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers